179 results on '"Fulciniti M"'
Search Results
2. Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma
3. P881: CDK7 CONTRIBUTES TO METABOLIC REPROGRAMMING IN MM CELLS THROUGH C-MYC MEDIATED TRANSCRIPTIONAL CONTROL OF GLYCOLYTIC GENES
4. Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma
5. Targeting homologous recombination and telomerase in Barrett’s adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth
6. Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy
7. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
8. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo
9. IL-17 Promotes Tumor cell Growth and Survival, and Inhibits Immune Function in Myeloma: B623
10. Targeting the Sp1 Transcription Factor in Multiple Myeloma: B569
11. Anti-DKK1 mAb (BHQ880) as a Potential Therapeutic Agent for Multiple Myeloma: B563
12. Targeting Myeloma Bone Disease via Activin A Inhibition: B357
13. A New Anti-Dkk-1 Antibody Targeting Myeloma Bone Disease: B203
14. CAL-101: A Selective Inhibitor of PI3K p110Δ for the Treatment of Multiple Myeloma: B037
15. CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity via c-Maf Mediation: B026
16. Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study
17. PF588 SIGNIFICANT POM EFFECT ON THE IMMUNE-CELL PROFILES IN B, T AND NK SUBSETS IN A LARGE COHORT CLINICAL TRIAL IN RELAPSED/REFRACTORY MYELOMA
18. S119 THE ROLE OF RECURRENT SOMATIC ALTERATIONS IN THE NON-CODING GENOME WITH FUNCTIONAL IMPLICATIONS IN MM
19. PF561 DUAL-TARGETING OF PROMOTER AND ENHANCER DRIVEN PROCESSES SUPPRESSES MYELOMA CELL GROWTH AND VIABILITY VIA PERTURBATION OF THE MYELOMA PROLIFERATIVE PROGRAM
20. S120 CHRONOLOGY OF COPY NUMBER ALTERATIONS FROM PRECURSORS TO MULTIPLE MYELOMA: WHAT COMES FIRST?
21. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma
22. Nucleotide excision repair is a potential therapeutic target in multiple myeloma
23. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications
24. CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity via c-Maf Mediation
25. miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth
26. WHOLE EXOME SEQUENCING DEFINES CLONAL ARCHITECTURE AND GENOMIC EVOLUTION IN MULTIPLE MYELOMA
27. Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma
28. A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma
29. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma
30. Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma
31. Targeting homologous recombination and telomerase in Barrett’s adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth
32. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1
33. B026 CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity via c-Maf Mediation
34. B203 A New Anti-Dkk-1 Antibody Targeting Myeloma Bone Disease
35. B569 Targeting the Sp1 Transcription Factor in Multiple Myeloma
36. B563 Anti-DKK1 mAb (BHQ880) as a Potential Therapeutic Agent for Multiple Myeloma
37. B037 CAL-101: A Selective Inhibitor of PI3K p110D for the Treatment of Multiple Myeloma
38. B623 IL-17 Promotes Tumor cell Growth and Survival, and Inhibits Immune Function in Myeloma
39. B357 Targeting Myeloma Bone Disease via Activin A Inhibition
40. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells (Blood (2009) 113, 18, (4309-4318))
41. Targeting PI3K and RAD51 in Barrett's adenocarcinoma: Impact on DNA damage checkpoints, expression profile and tumor growth
42. The genomic landscape of structural variations and complex events in multiple myeloma
43. Analysis of mutations and structural variants to redefine the genomic landscape of multiple myeloma and its clinical implications
44. Mechanism of action of immunomodulatory agents in multiple myeloma.
45. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1
46. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf–mediated interactions with bone marrow stromal cells
47. HLA class I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells
48. Development of hyperdiploidy starts at an early age and takes a decade to complete.
49. Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity.
50. Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.